The breakout groups report back to the rest of the conference.
Professor Bas Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. He received his M.D. degree (with honour) at Leiden University Medical Centre in 1993. In 1994, he obtained his PhD degree in Leiden, based on a thesis entitled "Postural reflexes in Parkinson's disease". He was trained as a neurologist between 1994 and 2000, also at Leiden University Medical Centre. He received additional training as a movement disorders specialist during fellowships at "The Parkinson's Institute", Sunneyvale, California (with Dr. J.W. Langston), and at the Institute of Neurology, Queen Square, London (with Prof. N.P. Quinn and Prof. J.C. Rothwell). In 2002, he founded and became Medical Director of the Parkinson Centre Nijmegen (ParC), which was recognised from 2005 onwards as centre of excellence for Parkinson's disease. Together with Dr. Marten Munneke, he also developed ParkinsonNet, an innovative healthcare concept that now consists of 64 professional networks for Parkinson patients covering all of the Netherlands (www.parkinsonnet.nl). In September 2008, he was appointed as Professor of Neurology, with movement disorders as special area of interest. He is currently President of the International Society for Gait and Postural Research, and is on the editorial board for several national and international journals. Since 2009, he is member of the European Section Executive Committee of the Movement Disorder Society. In 2009, he also joined the board of ZonMw (The Netherlands Organisation for Health Research and Development). He currently has two main research interests: cerebral compensatory mechanisms, especially in the field of gait & balance; and healthcare innovation, aiming to develop and scientifically evaluate patient-centred collaborative care. For this latter purpose, Prof. Bloem co-founded MijnZorgnet (together with Prof. Jan Kremer), a service provider that delivers web-based communities for both patients and health professionals. Prof. Bloem has published over 300 publications, including more than 230 peer-reviewed international papers.
Philip E. Bourne PhD is a Professor in the Department of Pharmacology and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego, Associate Director of the RCSB Protein Data Bank and an Adjunct Professor at the Sanford Burnham Institute. He is a Past President of the International Society for Computational Biology. He is an elected fellow of the American Association for the Advancement of Science (AAAS), the International Society for Computational Biology (ISCB) and the American Medical Informatics Association (AMIA). He is the co-founder and inaugural and current Editor-in-Chief of the open access journal PLoS Computational Biology and a long standing member of the National Science Foundation, National Institutes of Health and Genome Canada panels responsible for reviewing proposals relating to computational biology.
Kelly Edwards, Ph.D., is an Associate Professor in the Department of Bioethics & Humanities at the University of Washington School of Medicine and Adjunct Associate Professor in the Department of Environmental and Occupational Health. Her training is in Medical Ethics and Philosophy of Education. She teaches and develops curriculum in ethics and professionalism for medical students, residents, and faculty. Dr. Edwards has also served as a curriculum advisor and project co-director for two HRSA contracts to develop genetics curriculum for primary care physicians. She is involved in a number of collaborations that examine justice concerns in genetics research, ethics of community-based research, and international governance models for biobanks.
Dr. Edwards' research interests include clinical decision making, effective approaches to ethics education, and research ethics. Special interests include cultural differences, communication, feminist and narrative approaches to bioethics, research ethics, and integrating ethics into medicine and science education.
She joined the faculty at the Institute for Public Health Genetics in Spring 2002 and directs the Ethics and Outreach Core for the NIEHS-funded Center for Ecogenetics and Environmental Health.
Dr. Ford-Hutchinson is Senior Vice President, Vaccines Research and Development Merck Research Laboratories. He has a 30 year record of success at Merck & Co., Inc. and was Senior Vice President and Site Head of Merck Frosst Canada during the development of SingulairÂ® for the treatment of adult and pediatric asthma and allergic rhinitis and the discovery of selective COX-2 inhibitors for the treatment of osteoarthritis and pain. Before joining Merck he was a lecturer in the Chemical Pathology Department at Kings College Hospital Medical School in London doing leukotriene and prostaglandin research. Dr. Ford-Hutchinson obtained his Bachelorâ€™s Degree in Biochemistry from the University of Birmingham, a Masters Degree in Molecular Enzymology from the University of Warwick, and a Ph.D. in Biochemistry from the University of London.
President, Co-Founder and Director of Sage Bionetworks. Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Francois Grey is Professor of Distributed Scientific Computing at the Center for Nano and Micro Mechanics.
Francois Grey has helped to establish the new field of citizen cyberscience in China, through the CNMM project Computing for Clean Water in collaboration with IBMâ€™s World Community Grid. Citizen cyberscience involves adapting scientific challenges so that non-expert volunteers can contribute computing power and brain power to solving them in a fast, low-cost and reliable way. Francoisâ€™ current interests include applications of citizen cyberscience to nanotechnology and biotechnology and geotagging.
Prior to joining CNMM in July 2010, Francois was a Visiting Professor and Senior International Expert with the Chinese Academy of Sciences (CAS), helping to establish the CAS@home volunteer computing project at the Institute of High Energy Physics of CAS in Beijing. He is currently a fellow of the Shuttleworth Foundation for his work in promoting citizen cyberscience in the developing world, and is coordinator of the Citizen Cyberscience Centre, a partnership between CERN, the UN Institute for Training and Research and the University of Geneva.
Thomas R. Insel, M.D., is Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating the knowledge needed to understand, treat, and prevent mental disorders. His tenure at NIMH has been distinguished by groundbreaking findings in the areas of practical clinical trials, autism research, and the role of genetics in mental illnesses.
Prior to his appointment as NIMH Director in the Fall 2002, Dr. Insel was Professor of Psychiatry at Emory University. There, he was founding director of the Center for Behavioral Neuroscience, one of the largest science and technology centers funded by the National Science Foundation and, concurrently, director of an NIH-funded Center for Autism Research. From 1994 to 1999, he was Director of the Yerkes Regional Primate Research Center in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at NIMH studying the neurobiology of complex social behaviors. He has published over 250 scientific articles and four books, including the Neurobiology of Parental Care (with Michael Numan) in 2003.
Dr. Insel has served on numerous academic, scientific, and professional committees and boards. He is a member of the Institute of Medicine, a fellow of the American College of Neuropsychopharmacology, and is a recipient of several awards including the Outstanding Service Award from the U.S. Public Health Service. Dr. Insel graduated from the combined B.A.-M.D. program at Boston University in 1974. He did his internship at Berkshire Medical Center, Pittsfield, Massachusetts, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.
Jason Johnson is the Executive Director of the Informatics IT Department at Merck.
Over the last eight years, François Taddei has created the CRI (Center for Research and Interdisciplinary) in Paris. CRI’s main role is to promote new pedagogies to help creative students take initiatives and develop their research projects, with the help of mentors, research institutions, private companies, and foundations, such as the Bettencourt Foundation, which has supported many student-created activities. These activities range from the first French synthetic biology team (for the MIT-sponsored iGEM competition) to the Paris-Montagne science festival and the Science Académie, an outreach program that allows high schools students from deprived neighbourhoods to discover the creativity of science. The CRI offers three programs integrated in the Liliane Bettencourt curriculum: a new undergrad program, a Master’s degree (Innovative Approaches to Research and Education, IARE), and a doctoral school (Frontiers of Life, FdV). CRI‘s dedicated facilities host visiting professors, a wide choice of courses and several student discussion clubs.
François Taddei has taken the lead of the new Institute for Learning Through Research that has been selected in March 2012 by the International Scientific Committee of the National Innovative Training Program (IDEFI) of the French ministry of research.
François Taddei also heads the Evolutionary Systems Biology team at a unit of the French National Institute of Health & Medical Research (INSERM) in Paris-Descartes University’s Medical School. His work has produced many publications in general-interest scientific journals, and has been recognized by several international and national awards. François Taddei participates in various working groups on the future of research and education (France 2025, OECD, EU, etc.).
Sharon F. Terry is President and CEO of Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. Genetic Alliance enables individuals, families and communities to reclaim their health and become full participants in translational research. She is the founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). As co-discoverer of the gene associated with PXE, she holds the patent for ABCC6 to act as its steward and has assigned her rights to the foundation. She developed a diagnostic test and conducts clinical trials. Terry is also a co-founder of the Genetic Alliance Registry and Biobank. She is the author of more than 100 peer-reviewed articles. In her focus at the forefront of consumer participation in genetics research, services and policy, she serves in a leadership role on many of the major international and national organizations.
Dr. Markus Warmuth joined H3 Biomedicine as Chief Scientific Officer in August 2011 and became President and Chief Executive Officer on October 1, 2011. Markus brings significant experience in cancer biology, drug discovery and clinical oncology to H3. During his career as a pharmaceutical industry research executive, he has successfully built and shaped oncology research groups and portfolios.
Prior to joining H3, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site. There, he oversaw a significant part of NIBRâ€™s global oncology drug discovery portfolio from target discovery to clinical development.
Markus studied and received his doctorate in Medicine from the Ludwig-Maximilians-University of Munich, Germany. He trained in Internal Medicine and Oncology at the University of Munich. From 1998 to 2002, he had an appointment as a principal scientist with the â€œClinical Cooperation Group Signalingâ€ at the German National Research Center of Environment and Health (GSF), where he studied the mechanism of action of and resistance to multiple small molecule kinase inhibitors in leukemia and lymphoma.
Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (seedialysis, prosthesis), and instruments for monitoring biological processes. Development has been particularly rapid in the area of artificial organs, which culminated in the implantation of an artificial heart into a human being in 1982. Bioengineers also develop equipment that enables humans to maintain body functions in hostile environments, such as the space suits worn by astronauts during extravehicular maneuvers.